Biotech & Pharma

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

24 sec read57 views0 listens

Novartis shares dropped sharply after its neuromuscular drug candidate, del-desiran, failed a pivotal Phase III trial. This setback, along with two others in the same week, highlights the challenges in developing therapies for complex diseases and underscores risks for investors in biotech pipelines. Developers should watch Novartis's next steps regarding del-desiran’s future development path.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & Pharma20 hours ago34 sec read

Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

Eli Lilly has presented early clinical data for its experimental GIP/GLP-1 receptor agonist, brenipatide, which demonstrates a favorable safety profile and supports once-weekly dosing for potential use in substance use, psychiatric, and immunological...

Ali Nemati

AI & Machine Learning1 day ago30 sec read

I quit being a trial lawyer to become a comedian. I loved my job but knew I was ready for something different.

Paul Farahvar, formerly a trial lawyer who even won a case before the Illinois Supreme Court, has transitioned to a full-time stand-up comedian after encouragement from Bob Saget. This shift highlights a growing trend of professionals seeking new cha...

Ali Nemati

Entertainment1 day ago34 sec read

Nick Reiner says money from grandfather Carl Reiner should be available for his defense

Nick Reiner, who is awaiting trial for the murders of his parents, Rob and Michele Reiner, has filed legal documents requesting access to funds from a trust. His legal team is arguing that a portion of the $1.6 million trust, inherited from his grand...

Ali Nemati